RYBREVANT

Phase 2Biologic

Johnson & Johnson

RYBREVANT is one of 43 biologic programs targeting Head and Neck Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[2]

Indication

Head and Neck CarcinomaActive, not recruiting

Lung CarcinomaUnknown

Head and Neck CarcinomaPhase 2

Active, not recruiting

Lung CarcinomaPreclinical

Unknown

Competition

Competitive Landscape

27 competitors in Lung Carcinoma

#DrugCompanyPhaseTrials

Iressa

Lumakras

Afinitor

Aurlumyn

BBTG International Inc.

Approved

—5

Chantix

PPrism Pharmaceuticals

Approved

—6

Navelbine

PPierre Fabre Medicament

Paraplatin

1 8

Ilaris

Taxotere

3 10

Caprelsa

GGenzyme, a Sanofi Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Regulatory

FDA Approval Timeline[3]

May 21, 2021

RYBREVANT

BLA BLA761210

Sources

References

[1]
ChEMBL — RYBREVANT compound record. European Bioinformatics Institute (EMBL-EBI).
[2]
Open Targets Platform — Drug–disease associations for RYBREVANT. EMBL-EBI & Wellcome Sanger Institute.
[3]
OpenFDA — FDA approval records (BLA BLA761210). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[1]
Highest Phase: Phase 2
Company: Johnson & Johnson

RYBREVANT

Status by Indication[2]

Competitive Landscape

FDA Approval Timeline[3]

References

Drug Info

Quick Facts

Related News